First patient in the UK recruited to cardiovascular research trial
Congratulations to the cardiovascular research team at Manchester Royal Infirmary (MRI) who recruited the first patient in the UK to a study investigating a new treatment for people with severe Hypertriglyceridemia (Shtg) at risk of developing acute pancreatitis.
The REGN1500 study, led locally by Dr Handrean Soran, Consultant Physician and Endocrinologist at the Cardiovascular Clinical Trials Unit (CVTU), is investigating the safety and efficacy of a drug in lowering elevated levels of cholesterol in people with severe hypertriglyceridemia (elevated fat levels) which can clog-up arteries and lead to future health problems.
Whilst it is important to help reduce risk factors from increased cholesterol levels by modifying diet, stopping smoking and increasing physical activity, people living with Shtg are at a greater risk of developing cardiovascular diseases such as acute pancreatitis and require medication such as statins to help lower their levels.
Regeneron Pharmaceuticals, Inc. a leading science-based biopharmaceutical company who is sponsoring the REGN1500 trial.